SCHEDULE: Soleus Capital Discloses 1% Stake in Jasper Therapeutics

Soleus Capital and affiliated entities have filed a Schedule 13G reporting a combined 1% beneficial ownership stake in Jasper Therapeutics, Inc.

Summary

• The filing represents an amendment to a Schedule 13G, confirming that Soleus Capital Management, L.P. and its affiliates beneficially own 276,312 shares of Jasper Therapeutics, Inc. common stock.
• This aggregate holding represents approximately 1.0% of the company's total outstanding common stock, based on 27,996,819 shares outstanding as of March 25, 2026.
• The reporting persons certify that these securities were not acquired for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard institutional portfolio activity with no impact on company operations.

Positives

• The filing confirms institutional investment interest in Jasper Therapeutics.
• The reporting entities have explicitly stated they are passive investors, reducing concerns regarding potential hostile takeover or activist intervention.

Negatives

• The total beneficial ownership of 1% is relatively minor and does not represent a significant controlling interest in the company.

Risks

• The investment is subject to the general market risks associated with Jasper Therapeutics' business operations and the biotechnology sector.

Future Outlook

The filing does not provide forward-looking guidance regarding the issuer's business, as it is a passive ownership disclosure.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard regulatory disclosures for institutional investors holding less than 5% of a company's stock, indicating passive portfolio management rather than strategic shifts in the biotech sector.

Comparison to Industry Standards

• The disclosure follows standard SEC requirements for institutional investors under the Securities Exchange Act of 1934.
• The 1% ownership level is consistent with diversified portfolio holdings typical of private equity and hedge fund management firms.

Stakeholder Impact

• Minimal impact on shareholders as the filing confirms passive investment status.

Next Steps

• The reporting persons will continue to monitor their investment in accordance with their internal investment mandates.

Key Dates

Keywords

Jasper Therapeutics, Soleus Capital, Schedule 13G, Biotechnology, Institutional Ownership, Common Stock